Stellate

Stellate Therapeutics is an international biotech company with headquarters in Paris, France, and a significant presence in New York City, USA. The company specializes in developing microbiome-derived small molecules into first-in-class therapies aimed at treating neurological diseases. Stellate Therapeutics operates in the biotech and pharmaceutical markets, focusing on innovative treatments that leverage the gut-brain axis—a complex communication network between the gut and the brain. This approach aims to address unmet medical needs in neurology by targeting the microbiome, the community of microorganisms living in the human body.

The company's business model revolves around research and development (R&D) of these novel therapies, which involves extensive laboratory work, clinical trials, and regulatory approvals. Stellate Therapeutics generates revenue through partnerships with larger pharmaceutical companies, grants, and potentially through the commercialization of its proprietary therapies once they receive regulatory approval.

Stellate Therapeutics serves a diverse range of clients, including healthcare providers, hospitals, and patients suffering from neurological conditions. The company is also actively seeking highly qualified individuals to join its team, as evidenced by its current job openings for positions such as Senior Research Associate and Research Scientist.

Keywords: biotech, microbiome, neurological diseases, gut-brain axis, small molecules, therapies, R&D, clinical trials, pharmaceutical partnerships, innovation.